Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2025-07-24
DOI
https://doi.org/10.1002/jha2.70095
Citations
1
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria

Karoline A. Meagher, Christopher Hartford, Steven Sherman, Lorah Perlee et al.
1 citations
eJHaem
Complement system in diseases
0.80
article

Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria

Karoline A. Meagher, Christopher Hartford, Steven Sherman, Lorah Perlee, Amal Souttou, Quang P. Nguyen, Jun Ho Jang, Kosalai Kal Mohan, Raymond Wong, Rodrigo Pavani, Diana Rofail, Lisa Aurand, Richard J. Kelly
article en
1 citations

Abstract

No abstract available for this paper.
eJHaemVol. 6(4)
Chinese University of Hong Kong (HK), Regeneron (United States) (US), St James's University Hospital (GB), Samsung Medical Center (KR), Prince of Wales Hospital (CN), Sungkyunkwan University (KR)
Regeneron Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 26%
Complement system in diseases
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria — Karoline A. Meagher, Christopher Hartford, et al. · eJHaem (2025) | TGRS Research Map | TGRS